Bacillus anthracis exosporium lipoprotein GBAA0190 (GBAA0190)

Bacillus anthracis exosporium lipoprotein GBAA0190 is a prominent surface-exposed protein located on the outermost layer of the anthrax spore, known as the exosporium. This protein plays a critical role in the structural integrity of the spore and serves as a primary interface between the pathogen and the host's immune system during the initial stages of infection. Because the exosporium is the first part of the spore encountered by host macrophages, GBAA0190 is a significant target for the development of next-generation anthrax vaccines and diagnostic tools. Research indicates that GBAA0190 is highly immunogenic, eliciting strong antibody responses that can enhance the clearance of spores through opsonophagocytosis. While current anthrax vaccines primarily target the Protective Antigen (PA) secreted by vegetative cells, incorporating spore surface antigens like GBAA0190 may provide more comprehensive protection by targeting the dormant spore stage. Therapeutic strategies focusing on this lipoprotein aim to prevent the transition from spore to vegetative cell, effectively halting the progression of the disease at its earliest point.

Other names

BAS0166Exosporium lipoprotein GBAA0190Anthrax spore surface antigenBacillus anthracis lipoprotein 0190

Vaccines and antibodies targeting GBAA0190 aim to induce neutralizing immunity or facilitate opsonophagocytosis of Bacillus anthracis spores, thereby preventing the germination and systemic spread of the bacteria within the host.